Core Viewpoint - Dong'e Ejiao reported steady growth in its 2025 semi-annual results, with significant improvement in operating cash flow compared to the first quarter [1][2]. Financial Performance - The company achieved operating revenue of 3.051 billion yuan, a year-on-year increase of 11.02% [1]. - Net profit attributable to shareholders reached 818 million yuan, up 10.74% year-on-year [1]. - The net profit after deducting non-recurring gains and losses was 788 million yuan, reflecting a 12.58% increase [1]. - The net cash flow from operating activities was 965 million yuan, a growth of 4.70% [1][2]. Market Position and Strategy - Dong'e Ejiao, a leading enterprise in the traditional Chinese medicine industry, has maintained a growth trend in recent years, supported by the expanding market for traditional Chinese medicine [2]. - The company is implementing the "1238" strategy to enhance its core business and explore potential products, focusing on the integration of the gel industry chain [1][4]. - Dong'e Ejiao's two core products, Dong'e Ejiao blocks and compound Ejiao syrup, hold nearly 40% market share in the qi and blood supplement category, with Dong'e Ejiao blocks dominating at approximately 70% market share [4]. Dividend Policy - The company announced a dividend plan to distribute 817 million yuan to shareholders, representing 99.94% of the net profit for the period [3]. - Since its first dividend in 1999, Dong'e Ejiao has cumulatively distributed 10.104 billion yuan, demonstrating stable long-term dividend capability [3]. Growth Initiatives - Dong'e Ejiao is actively developing its "second growth curve" with brands like "Royal Weichang 1619" and "Zhuangben," targeting the men's health market [5][6]. - The "Royal Weichang 1619" brand has seen over 150% revenue growth, with its flagship product achieving a 666% increase year-on-year [5]. - The "Zhuangben" brand, launched in late 2024, has quickly gained traction, focusing on a product matrix that meets consumer needs [6]. Future Outlook - The company plans to continue its dual-driven growth model of pharmaceuticals and health consumer products, reinforcing the value of its core products while expanding its men's health product matrix [6].

Group 1: Share Repurchase and Market Strategy - The company plans to continue researching share repurchase as a tool for market confidence and stock price stability, focusing on high dividend payouts as a primary investor return method [1] - The company aims to enhance brand engagement with younger consumers through product innovation and cultural initiatives, including the launch of convenient packaging and live streaming for targeted outreach [1] Group 2: Water Source Protection - The local government prioritizes the protection of the underground water source, which is rich in trace elements, ensuring high-quality and sustainable water supply through strict testing [2] Group 3: Pricing and Product Strategy - A systematic pricing governance plan is being implemented to create a sustainable pricing ecosystem for core products, transitioning from reliance on price increases to structural growth [3] - The company will dynamically adjust product prices based on supply and demand, optimizing pricing mechanisms for different consumer habits and product innovations [6] Group 4: Management and Strategic Execution - The management team will remain stable and committed to executing the "1238" strategy for steady business development [4] Group 5: Raw Material Supply Assurance - A dual-circulation raw material supply system is established, ensuring stable supply from domestic and international sources, while enhancing the utilization rate of donkey skin through research collaborations [5] Group 6: New Product Development - The company is focusing on the "Muntjac deer industry" and "Cistanche development" as new product directions, aiming for growth in high-potential segments [7]

Group 1: Future Business Strategy - Dong-E E-Jiao will adhere to the "1238" strategy, focusing on the integration of the gelatin industry chain and enhancing its core business [1] - The company aims to improve digital capabilities and drive high-quality growth, aspiring to become a trusted leader in health supplements [1] Group 2: Investment and Acquisition Plans - Investment and acquisitions are key components of the "1238" strategy, with a focus on potential targets in the health supplement sector [1] - The company is implementing a "dual-wheel drive" strategy for investment direction, particularly in pharmaceuticals and health consumer products [2] Group 3: Raw Material Supply Assurance - The company emphasizes the sustainable supply of donkey hide, focusing on both domestic and international markets [3] - Efforts include establishing a supply network and promoting policy guidance in key countries to ensure a stable supply chain [3] Group 4: New Product Development - The "Zhuangben" brand will focus on upstream material acquisition and introduce innovative products to the market [4] - The company plans to enhance brand recognition for "Ejiao Dates" and develop a variety of health snack products [4] - A new category for "Ejiao Bird's Nest" will be created, with a focus on brand optimization and product efficacy verification [4] Group 5: Profit Distribution and Dividends - Since its listing in 1996, the company has distributed dividends 26 times, totaling 8.469 billion yuan, with an average payout ratio of 65.75% [6] - For 2024, the company plans to distribute 818 million yuan, with a payout ratio of 99.87% [6] Group 6: Revenue Projections - In 2024, Dong-E E-Jiao block products are expected to account for approximately 45% of total revenue, while compound Ejiao syrup is projected to contribute nearly 35% [6] Group 7: Brand Development Initiatives - The "Royal Weichang 1619" brand aims to establish itself as a leading men's health brand, focusing on product and category expansion [7] - The "Peach Blossom Princess Ejiao Cake" brand will undergo a comprehensive brand renewal to capture the mainstream beauty market [7] Group 8: Financial Performance Insights - The company experienced a decline in cash flow and an increase in accounts receivable due to strategic credit management and increased procurement of raw materials [8]

Group 1: Company Strategy and Market Position - In 2025, Dong'e Ejiao will focus on the "1238" strategy, emphasizing "growth and breakthrough" as its operational theme, and will implement the "four remakes" to enhance the entire gelatin industry chain [1] - The company holds a combined market share of 38.1% in the Qi and Xue supplement category, with Dong'e Ejiao block at 67.3% and Compound Ejiao Syrup at 31.9% [2] - Dong'e Ejiao aims to strengthen its core business and expand potential products through differentiated innovation and the establishment of technological barriers [1][2] Group 2: Financial Performance and Revenue - In Q1 2025, the company achieved online revenue of approximately 340 million yuan, a year-on-year increase of about 20% [2] - The online revenue breakdown includes: Ejiao block at approximately 120 million yuan (up nearly 15%), Compound Ejiao Syrup at approximately 60 million yuan (up nearly 60%), and Ejiao powder at approximately 60 million yuan (up nearly 50%) [2] - The overall gross margin is maintained at around 70%, with a slight increase in Q1 due to reduced costs from centralized procurement [7] Group 3: Inventory and Sales Management - The reasonable inventory level for Dong'e Ejiao block and Compound Ejiao Syrup is set at six months of terminal market sales, while for Taohua Ji Ejiao cake, it is 1.5 months [2] - The current channel inventory is at a healthy level, and terminal pure sales are progressing steadily [2] Group 4: Future Plans and Dividends - Since its first dividend in 1999, the company has distributed a total of 8.469 billion yuan over 26 occasions, with an average payout ratio of 65.75% [6] - The proposed dividend for 2024 is 818 million yuan, with a payout ratio of 99.70% [6] - The company plans to maintain a stable and proactive dividend policy based on its operational development, profitability, cash flow, and shareholder interests [6] Group 5: Challenges and Adjustments - The increase in accounts receivable in Q1 2025 is attributed to the implementation of a credit management strategy and increased procurement costs for strategic materials [4] - The company is addressing the small proportion of insurance payments for Compound Ejiao Syrup and aims for sustainable growth in this area [5]

Investment Rating - The investment rating for the company is "Buy" (maintained) [3] Core Insights - The company achieved a revenue of 5.921 billion yuan in 2024, representing a year-on-year growth of 25.57%, and a net profit attributable to the parent company of 1.557 billion yuan, up 35.29% year-on-year [7] - The company is actively implementing its "1238" strategy, which focuses on a dual-driven development model of pharmaceuticals and health consumer products, along with a three-industry integration in the gel product chain [7] - The company plans to enhance sales investment in 2024, aiming for growth and breakthroughs in 2025, with a sales expense of 1.973 billion yuan, an increase of 32.77% year-on-year [7] - The gross profit margin for 2024 is projected at 72.42%, an increase of 2.18 percentage points year-on-year, primarily due to the higher proportion of high-margin gel products [7] - The company has shown significant improvement in operational efficiency, with accounts receivable turnover days reduced by 14.27 days to 23.51 days [7] - The company completed its first interim cash dividend of 737 million yuan in 2024, with a dividend payout ratio of 99.77% [7] - The forecast for net profit attributable to the parent company for 2025-2027 is 1.943 billion yuan, 2.359 billion yuan, and 2.860 billion yuan, respectively, with corresponding growth rates of 24.80%, 21.41%, and 21.25% [7] Financial Summary - Revenue projections for 2024, 2025E, 2026E, and 2027E are 5.921 billion yuan, 6.972 billion yuan, 8.074 billion yuan, and 9.283 billion yuan, respectively, with growth rates of 25.57%, 17.75%, 15.80%, and 14.97% [3] - The projected earnings per share (EPS) for 2024, 2025E, 2026E, and 2027E are 2.42 yuan, 3.02 yuan, 3.66 yuan, and 4.44 yuan, respectively [3] - The price-to-earnings (P/E) ratio is expected to decrease from 24.29 in 2024 to 13.22 in 2027 [3]